Challenges of Phase III study design for trials of new drug regimens for the treatment of TB

Patrick PJ Phillips; Andrew J Nunn

doi:10.4155/fmc.10.221

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB

Future Medicinal Chemistry ◽

10.4155/fmc.10.221 ◽

2010 ◽

Vol 2 (8) ◽

pp. 1273-1282 ◽

Cited By ~ 5

Author(s):

Patrick PJ Phillips ◽

Andrew J Nunn

Keyword(s):

Study Design ◽

Phase Iii ◽

New Drug ◽

Drug Regimens ◽

Phase Iii Study

Download Full-text

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design

Future Oncology ◽

10.2217/fon-2018-0070 ◽

2018 ◽

Vol 14 (21) ◽

pp. 2103-2113 ◽

Cited By ~ 24

Author(s):

Eric Pujade-Lauraine ◽

Keiichi Fujiwara ◽

Samuel S Dychter ◽

Geeta Devgan ◽

Bradley J Monk

Keyword(s):

Ovarian Cancer ◽

Study Design ◽

Phase Iii ◽

Resistant Refractory ◽

Platinum Resistant ◽

Phase Iii Study

Download Full-text

2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP)

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(11)70600-9 ◽

2012 ◽

Vol 18 ◽

pp. S134 ◽

Cited By ~ 3

Author(s):

R. Mills ◽

D. Bahr ◽

H. Williams

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Study Design ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.06.007 ◽

2012 ◽

Vol 13 (6) ◽

pp. 505-509 ◽

Cited By ~ 24

Author(s):

Edward B. Garon ◽

Dachuang Cao ◽

Ekaterine Alexandris ◽

William J. John ◽

Sergey Yurasov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Study Design ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

Future Oncology ◽

10.2217/fon-2017-0616 ◽

2018 ◽

Vol 14 (11) ◽

pp. 1035-1047 ◽

Cited By ~ 40

Author(s):

Paul G Richardson ◽

Michel Attal ◽

Frank Campana ◽

Solenn Le-Guennec ◽

Ai-Min Hui ◽

...

Keyword(s):

Multiple Myeloma ◽

Study Design ◽

Phase Iii ◽

Refractory Multiple Myeloma ◽

Phase Iii Study

Download Full-text

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.05.009 ◽

2012 ◽

Vol 13 (6) ◽

pp. 500-504 ◽

Cited By ~ 61

Author(s):

David R. Spigel ◽

Martin J. Edelman ◽

Tony Mok ◽

Kenneth O'Byrne ◽

Luis Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Standard Chemotherapy ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

Clinical Investigation ◽

10.4155/cli.12.137 ◽

2013 ◽

Vol 3 (1) ◽

pp. 29-35 ◽

Cited By ~ 1

Author(s):

Michael Boyer ◽

Pasi Antero Jänne ◽

Tony Mok ◽

Kenneth O’Byrne ◽

Luis Paz-Ares ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

0174 A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: Study design of the new primary endocrine-therapy origination study [NEOS (N-SAS BC06)]

The Breast ◽

10.1016/s0960-9776(09)70197-3 ◽

2009 ◽

Vol 18 ◽

pp. S62 ◽

Cited By ~ 2

Author(s):

H. Iwata ◽

N. Masuda ◽

T. Toyama ◽

N. Taira ◽

Y. Yamamoto ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Endocrine Therapy ◽

Study Design ◽

Postmenopausal Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Study ◽

Primary Endocrine Therapy

Download Full-text

A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol

Journal of the Peripheral Nervous System ◽

10.1111/jns.12267 ◽

2018 ◽

Vol 23 (2) ◽

pp. 108-114 ◽

Cited By ~ 6

Author(s):

David R. Cornblath ◽

Hans‐Peter Hartung ◽

Hans D. Katzberg ◽

Ingemar S. J. Merkies ◽

Pieter A. van Doorn

Keyword(s):

Intravenous Immunoglobulin ◽

Study Design ◽

Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽

Phase Iii ◽

Phase Iii Study ◽

Different Doses

Download Full-text

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.3816/clc.2009.n.035 ◽

2009 ◽

Vol 10 (4) ◽

pp. 252-256 ◽

Cited By ~ 49

Author(s):

Jyoti D. Patel ◽

Philip Bonomi ◽

Mark A. Socinski ◽

Ramaswamy Govindan ◽

Shengyan Hong ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design

Future Oncology ◽

10.2217/fon-2019-0141 ◽

2019 ◽

Vol 15 (18) ◽

pp. 2073-2082 ◽

Cited By ~ 9

Author(s):

Daniel VT Catenacci ◽

Anteneh Tesfaye ◽

Mohamed Tejani ◽

Eric Cheung ◽

Peter Eisenberg ◽

...

Keyword(s):

Study Design ◽

Phase Iii ◽

Gastroesophageal Cancer ◽

Phase Iii Study ◽

Modified Folfox6

Download Full-text